New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article ...

Acute lymphoblastic leukemia (ALL ... The sensitivity and specificity of neutropenia, leukopenia, thrombocytopenia, anemia, and pancytopenia were 11.11% and 47.9%, 0% and 50%, 33.3% and 98.31%, 0% and ...

The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

It can be difficult to find out that you have acute lymphoblastic leukaemia (ALL). It’s normal to feel angry, sad, upset and shocked. You might worry about what will happen and how you will cope.

The start of NX-5948's CLL registrational trial in 2025 As of ... starting with warm Autoimmune Hemolytic Anemia (wAIHA), represents a significant growth opportunity. The autoimmune disease ...

The symptoms are largely due to the onset of anemia (characterized by the loss of red blood ... The two main types of acute leukemia are acute lymphocytic leukemia (ALL) and acute myeloid leukemia ...